Most patients in the trial were treated by surgeons who had received consulting payments from Warsaw, Ind.-based Zimmer. More than half of the patients in the trial were treated at medical centers that reported more than $100,000 in payments from the company, according to FDA’s review.
The FDA said one analysis of the company’s results showed a positive relationship between financial payments and clinical success for the device.